Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: Nonalcoholic steatohepatitis (NASH) is the outcome of interactions between overnutrition, energy metabolism, and adipose function. Obeticholic acid (OCA) improves steatosis in patients but for unknown reasons does not resolve NASH pathology. This study therefore investigated OCA effects in Wt mice, which develop obesity with atherogenic dietary feeding, and appetite‐dysregulated, Alms1 mutant foz/foz mice fed the same diet, which develop metabolic obesity and diabetes. Methods: OCA (1 mg/kg) was administered orally to female foz/foz mice and Wt littermates from weaning until 28 weeks. Adipose indices, glucose tolerance, and fatty liver pathology were studied. Experiments were repeated with OCA 10 mg/kg. Results: OCA reduced body weight and hepatic lipids and improved glucose disposal only in Wt mice. OCA limited Wt adipose expansion, altered morphometry in favor of small adipocytes, enhanced expression of genes indicating adipose browning, and reduced crown‐like structure number in visceral adipose tissue. foz/foz mice showed more crown‐like structures in all compartments; OCA failed to alter adipose morphometry, browning, inflammation, or improve NASH severity, even at 10 mg/kg. Conclusions: OCA improved adipose indices, glucose tolerance, and steatosis in a milder metabolic phenotype but failed to improve these factors in morbidly obese diabetic mice. These results help explain OCA's limited efficacy to reverse human NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Self-citationNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 3×
“33 (0–2) Normal (7), simple steatosis (2)”
BackgroundPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 1×
“receptor (FXR) (15,17), a nuclear receptor which, by regulating the expression of other transcription factors, reduces lipogenesis, suppresses de novo cholesterol biosynthesis, and increases b-oxidation of long chain FAs (18,19).”
BackgroundIntestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559 · cited 2×
“It remains unclear whether the reduction in adipose inflammatory recruitment produced by OCA treatment in Wt mice is a direct effect of FXR activation on adipogenic factors in adipocytes or whether intestinal FXR could exert beneficial effects on adipose inflammation via such mediators as fibroblast growth factor 15 (…”
BackgroundBile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
Fiorucci, S., & Distrutti, E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.001 · Cited by 539 · cited 2×
“It remains unclear whether the reduction in adipose inflammatory recruitment produced by OCA treatment in Wt mice is a direct effect of FXR activation on adipogenic factors in adipocytes or whether intestinal FXR could exert beneficial effects on adipose inflammation via such mediators as fibroblast growth factor 15 (…”
BackgroundVisceral and subcutaneous fat have different origins and evidence supports a mesothelial source
Chau, Y.-Y., Bandiera, R., Serrels, A., Martínez-Estrada, O. M., Qing, W., Lee, M., Slight, J., Thornburn, A., Berry, R., McHaffie, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2922 · Cited by 518 · cited 1×
“Quantification of mRNA and protein Adipose stromal vascular fractions (SVFs) were isolated from each adipose compartment (32).”
BackgroundGastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285 · cited 1×
“Adipose dysfunction and corresponding metabolic obesity are major risk factors for hepatic lipotoxicity in NASH (2,6-8,10-13).”
BackgroundMencarelli, A., Renga, B., Migliorati, M., Cipriani, S., Distrutti, E., Santucci, L., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901347 · Cited by 177 · cited 6×
“Liver lipidomic analyses were performed by gas chromatography for triglyceride, FC, and cholesteryl ester (CE) and by high-performance liquid chromatography for total FAs (30).”
BackgroundInfluential
Cited by
Macrophage functions in lean and obese adipose tissue
Thomas, D., & Apovian, C. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.005 · Cited by 316
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“It is important therefore to control for drug-induced weight loss in rodent models of NASH, for example, with agents like glucagon-like peptide 1 agonists and obeticholic acid.(51) A pathophysiological schema on factors contributing to fibrogenesis is presented in Fig.”
Self-citationMouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Self-citationBoland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4904 · Cited by 129
Metadata
- Authors
- Haczeyni, F., Poekes, L., Wang, H., Mridha, A. R., Barn, V., Geoffrey Haigh, W., Ioannou, G. N., Yeh, M. M., Leclercq, I. A., Teoh, N. C., & Farrell, G. C.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2016-11-02
- Volume
- 25
- Issue
- 1
- Pages
- 155-165
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2548766187
- Cited by
- 46
- References
- 13
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. https://app.cochat.ai/papers/10.1002/oby.21701
- The paper
- Haczeyni, F., Poekes, L., Wang, H., Mridha, A. R., Barn, V., Geoffrey Haigh, W., Ioannou, G. N., Yeh, M. M., Leclercq, I. A., Teoh, N. C., & Farrell, G. C. (2017). Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity. https://doi.org/10.1002/oby.21701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.